Curasight A/S Achieves First Milestone under collaboration with Curium Inc.
· USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE[®] for use in prostate cancer between Curasight A/S and Curium Inc. · Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE[®] PET imaging technology · Under the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercialization